TrialThe Lancet. Haematology2020

Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial.

Catherine S Diefenbach et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.